Phase 4Not yet recruiting

A Phase IV, Two-part, Open-label Study Assessing the Pharmacokinetics, Safety and Pharmacodynamics of Spironolactone Oral Suspension in Pediatric Patients

A Phase IV, Two-part, Open-label Study Assessing the Pharmacokinetics, Safety and Pharmacodynamics of Single and Multiple Doses of Spironolactone Oral Suspension in Pediatric Patients With Edema Due to Heart Failure or Cirrhosis

Sponsor
CMP Development, LLC (Industry)
Enrollment
96 planned
Conditions
Edema Due to Heart Failure or Cirrhosis
Interventions
Spironolactone Oral Suspension
Ages
children
Registry
NCT06021860

Full record on ClinicalTrials.gov

From the registry

This is a 2-part, 2 periods per part, open-label study with spironolactone oral suspension in pediatric patients with edema due to HF or hepatic cirrhosis. Both study parts will evaluate the safety, PK and PD of multiple doses of spironolactone in patients aged from birth to ≤17 years of age.

Primary outcomes

  • Part 1: Absorption rate constant (Ka) of spironolactone (time^-1) in the multiple-dose period
  • Part 2: Absorption rate constant (Ka) of spironolactone (time^-1) in the multiple-dose period
  • Part 1: Total clearance from plasma after oral administration (CL/F) of spironolactone in the multiple-dose period
  • Part 2: Total clearance from plasma after oral administration (CL/F) of spironolactone in the multiple-dose period

History

  1. Study completion expected

  2. Primary completion expected

  3. Expected to start

  4. Now not yet recruiting

    , from Status unknown to Not yet recruiting

  5. Completion moved to Jun 2028

    , from Mar 2025 to Jun 2028

  6. Last registry update

  7. Registered